

**SINGAPORE**  
BIOTECH INVEST

21-22 March 2017

Singapore Exchange (SGX)

**HONG KONG**  
BIOTECH INVEST

23-24 March 2017

KPMG Hong Kong

**AUSTRALIA-CHINA**  
BIOTECH INVEST

27-28 March 2017

Shanghai Marriott Hotel City Centre

### **Associate Professor David Anderson, PhD**

David Anderson is Deputy Director of the Burnet Institute in Melbourne, Australia, where he has worked since the Institute's formation in 1986, at which time he was completing his PhD with founding Director, Prof Ian Gust. Until recently he was responsible for coordination of R&D commercialisation at the Institute as well as leading the Diagnostics Development Laboratory and involvement in vaccine research projects. His research has led to 9 granted patent families and innovations including diagnostics for hepatitis E developed in collaboration with Beijing Medical University; the Visitect CD4 point of care test for monitoring of CD4+ T-cells in HIV and a new test for syphilis screening, both commercialised by Omega Diagnostics, Scotland, and a novel virus-like particle platform technology (Metavax™) commercialised by Artes Biotechnology, Germany. In 2013 he was awarded a "321" grant by the Nanjing Government to establish the Burnet spinoff company, Nanjing BioPoint Diagnostic Technology Ltd, of which he is CEO. Nanjing BioPoint subsequently completed an investment agreement in 2014 with Beijing GuoMinXinHe Group, to progress the development and commercialisation of a novel liver disease test. He is a passionate believer in the potential of Australian biotechnology, medical research and innovation, especially in the field of global health that closely reflects the Burnet Institute's mission, and in the synergies that are possible between Australian medical research and biotechnology and overseas partners such as in China, S.E. Asia and India.